GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » 3-Year EPS without NRI Growth Rate

Betta Pharmaceuticals Co (SZSE:300558) 3-Year EPS without NRI Growth Rate : -8.90% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co 3-Year EPS without NRI Growth Rate?

Betta Pharmaceuticals Co's EPS without NRI for the three months ended in Mar. 2024 was ¥0.22.

During the past 12 months, Betta Pharmaceuticals Co's average EPS without NRI Growth Rate was 606.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -8.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Betta Pharmaceuticals Co was 33.40% per year. The lowest was -48.70% per year. And the median was -8.90% per year.


Competitive Comparison of Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate falls into.



Betta Pharmaceuticals Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Betta Pharmaceuticals Co  (SZSE:300558) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Betta Pharmaceuticals Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines